Expertise in
94
conditions

Dr. Sreekanth Reddy

American Oncology Partners PA
Johns Creek, GA
Expertise in
94
conditions
Specialties:Oncology | Hematology Oncology | Hematology
Expertise in
94
conditions
OverviewInsuranceLocationsClinical Research

Overview

Sreekanth Reddy is an Oncologist and a Hematologist Oncology provider in Johns Creek, Georgia. Dr. Reddy is highly rated in 94 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Hodgkin Lymphoma, Pleuropulmonary Blastoma, Hemosiderosis, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in GA
Hospital Affiliations
Memorial Health Meadows Hospital
Northside Hospital Forsyth
Northside Hospital Cherokee
Northside Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Anthem
  •  Friday Health
  •  CareSource
  •  Humana

Locations

AMERICAN ONCOLOGY PARTNERS PA
6985 Mcginnis Ferry Rd, Suite 100, Johns Creek, GA 30097
678-726-6203

Additional Areas of Focus

Dr. Reddy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Talazoparib, Talazoparib Tosylate
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 8 Less Clinical Trials

3 Total Publications

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Journal: Journal for immunotherapy of cancer
Published: July 19, 2021
Similar Doctors
Expertise in
27
conditions
Dr. Melhem M. Solh
Hematology | Oncology
Expertise in
27
conditions
Dr. Melhem M. Solh
Hematology | Oncology

Blood And Marrow Transplant Group Of Georgia

5670 Peachtree Dunwoody Rd Ne, Suite 1000, 
Atlanta, GA 
 (15.3 mi)
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Melhem Solh is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Solh is highly rated in 27 conditions, according to our data. His top areas of expertise are Leukemia, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Solh is currently accepting new patients.

Expertise in
24
conditions
Dr. Asad Bashey
Hematology | Oncology
Expertise in
24
conditions
Dr. Asad Bashey
Hematology | Oncology

Blood And Marrow Transplant Group Of Georgia

5670 Peachtree Dunwoody Rd Ne, Suite 1000, 
Atlanta, GA 
 (15.3 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Asad Bashey is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Bashey is highly rated in 24 conditions, according to our data. His top areas of expertise are Leukemia, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bashey is currently accepting new patients.

Expertise in
28
conditions
Dr. Mehmet A. Bilen
Hematology Oncology | Hematology | Oncology
Expertise in
28
conditions
Dr. Mehmet A. Bilen
Hematology Oncology | Hematology | Oncology

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (20.8 mi)
404-778-7525
Languages Spoken:
English, Mandarin, Spanish, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mehmet Bilen is a Hematologist Oncology specialist and a Hematologist in Atlanta, Georgia. Dr. Bilen is highly rated in 28 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Tissue Biopsy. Dr. Bilen is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile